Total
0
Shares
Prescient Therapeutics (PTX) -CEO & Managing Director, Steven Yatomi - The Market Herald
CEO & Managing Director, Steven Yatomi
Source: PTX
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cancer treatment company Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs
  • PTX has an existing research agreement with Peter Mac focusing on cell therapy enhancement programs, which looks to improve the current CAR-T approaches
  • This new agreement extends the relationship between the parties to include the development of the OmniCAR platform
  • Under the terms of the research agreement, PTX will have access to the expertise and facilities of Peter Mac
  • On the market today, PTX is up 1.12 per cent, trading at 9 cents per share

Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs.

CAR-T is a type of cellular therapy that reprograms the immune cells of cancer patients to recognise and destroy cancerous cells.

As previously reported, PTX has an existing research agreement with Peter Mac focusing on cell therapy enhancement programs, which looks to improve the current CAR-T approaches.

This new agreement extends the relationship between the parties to include the development of the OmniCAR platform.

OmniCAR is a next-generation CAR T therapy platform that offers multiple advantages over its predecessor such as control, safety, flexibility and efficacy.

PTX is developing three OmniCAR programs, including next-generation CAR-T
therapies for acute myeloid leukaemia. Her2+ solid tumours and glioblastoma multiforme.

Under the terms of the research agreement, PTX will have access to the expertise and facilities of Peter Mac.

"We are delighted to deepen our ties with a world-class institute in Peter Mac. Prescient is committed to developing all three OmniCAR programs expediently, and to the highest standard," CEO and Managing Director Steven Yatomi-Clarke said.

"This latest research program with Peter Mac is an important part of Prescient’s development plans, which include institutional and commercial laboratories," he added.

On the market today, PTX is up 1.12 per cent, trading at 9 cents per share at 12:09 pm AEST.

PTX by the numbers
More From The Market Herald
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) completes US dual listing

Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The Market Herald Video

" US regulator approves expanded use of Avita Medical’s (ASX:AVH) RECELL System

The US regulator has approved the expanded use of Avita Medical’s (AVH) RECELL system in combination with meshed autographs to treat burns patients.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.
Microequities Asset Management (ASX:MAM) posts 140pc boost to half-yearly profit

" Patrys (ASX:PAB) receives $600k R&D tax incentive refund

Patrys (PAB), through its wholly owned Nucleus Therapeutics subsidiary, has received a research and development (R&D) tax incentive refund of $626,780 for the